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DObjectives: The CoreValve Extreme Risk US Pivotal Trial enrolled patients with symptomatic severe aortic
stenosis deemed unsuitable for surgical aortic valve replacement. Implants were attempted using transfemoral
access (n ¼ 489) or an alternative access (n ¼ 150). In present analysis, we sought to examine the safety and
efficacy of CoreValve transcatheter aortic valve replacement using alternative access.
Methods: The present study included 150 patients with prohibitive iliofemoral anatomy who were treated with
the CoreValve transcatheter heart valve delivered by way of the subclavian artery (n ¼ 70) or a direct aortic
approach (n ¼ 80). The echocardiograms were read by an independent core laboratory. The primary endpoint
was all-cause mortality or major stroke at 12 months.
Results: The preoperative aortic valve areawas 0.72 0.27 cm2 andmean aortic valvegradientwas 49.5 17.0mm
Hg. After the transcatheter aortic valve replacement, the effective aortic valve area was 1.82 0.64 cm2 at 1 month
and 1.85 0.51 cm2 at 12months. Themean aortic valve gradientwas 9.7 5.8mmHgat 30 days and 9.5 5.7mm
Hgat 12months. The death ormajor stroke ratewas 15.3% at 30days and 39.4% at 12months. The individual rate of
all-cause mortality and major stroke was 11.3% and 7.5% at 30 days and 36.0% and 9.1% at 12 months.
Conclusions: These data demonstrate that the CoreValve transcatheter heart valve delivered by an alternative
access provides a suitable alternative for treatment of extreme risk patients with symptomatic severe aortic ste-
nosis, who have prohibitive iliofemoral anatomy and no surgical options. (J Thorac Cardiovasc Surg
2014;148:2869-76)A
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Abbreviations and Acronyms
NYHA ¼ New York Heart Association
PARTNER ¼ Placement of Aortic Transcatheter
Valve (trial)
SAVR ¼ surgical aortic valve replacement
STS ¼ Society of Thoracic Surgeons
STS-PROM ¼ Society of Thoracic Surgeons-
Predicted Risk of Mortality
TAVR ¼ transcatheter aortic valve
replacement
THV ¼ transcatheter heart valve
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Dpatients have anatomy unsuitable for placement of a large
femoral sheath.
In such patients, alternative access with the balloon-
expandable SAPIEN (Edwards Life Sciences, Irvine, Calif)
transcatheter heart valve (THV) has been primarily
performed using a transapical approach.2 This technique
was not allowed in the Placement of Aortic Transcatheter
Valve (PARTNER) B inoperable trial but was used in the
PARTNER A trial in patients deemed at high risk of SAVR.
In patients with prohibitive iliofemoral vessels, the
CoreValve self-expanding THV (Medtronic, Inc, Minne-
apolis, Minn) has been used with alternative access sites,
including the subclavian artery5-7 and a direct aortic
approach with a medial partial sternotomy or right
thoracotomy.8-10 The CoreValve Extreme Risk US Pivotal
Trial evaluated patients deemed to have a prohibitive risk
for surgery and treated with this self-expanding THV using
the transfemoral access. A separate arm of the study was
designed for patients deemed unsuitable for iliofemoral
access and requiring alternative access procedures. Our
objective was to evaluate the clinical safety and efficacy
of self-expanding TAVR in patients at extreme risk for
SAVR in whom alternative access sites were used owing
to preclusive iliofemoral anatomy.METHODS
Patient Selection
The patient selection criteria for the CoreValve Extreme Risk US
Pivotal Trial have been previously described in detail.4 In brief, patients
with severe aortic stenosis and symptoms related to aortic valve disease
were eligible for the study. Severe aortic stenosis was defined as an aortic
valve area of0.8 cm2 or an aortic valve index of0.5 cm2/m2 and either a
mean aortic valve gradient>40 mmHg or a peak aortic valve velocity>4.0
m/s. Patients were considered at extreme risk if 2 cardiac surgeons and 1
interventional cardiologist at the clinical site estimated a 50% risk of
mortality or irreversible morbidity at 30 days with SAVR. This risk was
confirmed by 2 cardiac surgeons and 1 interventional cardiologist on a
National Screening Committee.
The anatomic exclusion criteria included an aortic annular diameter
<18 mm or>29 mm, moderate to severe mitral stenosis or severe mitral
regurgitation, or a dilated ascending aorta.4 Computed tomographic
angiography of the thoracic and abdominal aorta and common and external2870 The Journal of Thoracic and Cardiovascular Suriliac and femoral arteries was performed to determine the vessel caliber,
presence of calcification, and tortuosity. Patients with permissive femoral
and iliac arteries were enrolled in the CoreValve Extreme Risk US Pivotal
Trial Iliofemoral Arm. In the event that iliofemoral access was not suitable
for placement of an 18F sheath, the patients were considered for alternative
access.
Study Device
The CoreValve System consists of 3 components: the THV, delivery
catheter system, and compression loading system. The THV comprises a
self-expanding nitinol frame that supports a trileaflet porcine pericardial
valve. The valves available in the present report included those with 23-,
26-, 29-, and 31-mm diameters, treating patients with an annulus range
from 18 to 29 mm. The inflow portion of the frame is designed to conform
to the annulus and to stabilize the frame at the annular location. The lowest
12 mm of the frame contains a porcine pericardial skirt to seal the annulus.
The valve is located in a supra-annular position at the waist (constrained
portion) of the valve frame. The outflow portion of the valve frame is
constructed to support the valve commissures and orient the frame to facil-
itate laminar flow (Figure E1). All valve sizes are delivered using an 18F
catheter delivery system. The valve is deployed without rapid pacing and
is partially repositionable until annular contact with the THV has been
made.
Study Design
The CoreValve Extreme Risk US Pivotal Trial was a prospective,
multicenter, controlled, nonrandomized, single-arm clinical study per-
formed at 41 clinical sites in the United States (Table E1). The responsible
institutional review boards approved the study protocol, and all patients
provided written informed consent. The trial was conducted in accordance
with the International Conference on Harmonization, Good Clinical
Practice Guidelines, and the Declaration of Helsinki (ClinicalTrials.gov
identifier, NCT01240902).
This study was designed and funded by the study sponsor (Medtronic,
Inc). The study sponsor was responsible for the selection of the clinical
sites, monitoring the data, management of the case report forms, and statis-
tical analyses. An independent Clinical Events Committee (Table E2) adju-
dicated all major adverse clinical events. The Data and Safety Monitoring
Board was responsible for study oversight. The CoreValve US Steering
Committee reviewed the primary report and made the decision to submit
it for publication.
Subclavian Access
An open surgical approach was used to isolate the subclavian artery, and
an 18F sheath was advanced to the aorta over a stiff 0.035-in. guidewire
positioned in the left ventricle.
Direct Aortic Approach
A direct aortic approach was used with either a median hemisternotomy
or right thoracotomy between the first and second ribs. The 18F sheath was
advanced into the aorta over a stiff 0.035-in. guidewire positioned in the
left ventricle. The technical details of the subclavian and direct aortic
implantation approaches have been previously published.11
Procedural Details
The size of the selected bioprothesis was determined from the
pre-enrollment computed tomographic angiogram. Aspirin, 81 to 325
mg, was recommended before the procedure. After general anesthesia
was induced, anticoagulation with intravenous heparin or bivalirudin was
given to achieve an activated clotting time of 250 seconds. Through an
18F sheath, aortic valvuloplasty was performed with rapid ventricular
pacing. The self-expanding THV was then advanced across the aortic
valve. Contrast injections were performed through a pigtail cathetergery c December 2014
FIGURE 1. Study flow.
Reardon et al Acquired Cardiovascular Disease
A
C
Dpositioned at the base of the noncoronary sinus to guide positioning of the
inflow portion of the frame 2 to 6 mm inferior to the noncoronary basal
annulus. After valve deployment, the delivery catheter was removed, and
valve performance was evaluated using echocardiography, aortography,
and hemodynamic measurements. Dual antiplatelet therapy with aspirin,
81 mg daily, and clopidogrel, 75mg daily, were recommended for 3months
after the procedure. In the event that warfarin was indicated for other
reasons, aspirin, 81 mg daily, was also recommended.
Analysis Populations
The intended treatment population included all patients accepted by the
Screening Committee and who were then enrolled or treated through an
alternative access in the study by the clinical sites in the Alternative Access
Arm. A detailed assessment of the patient baseline comorbidities was
performed using the Society of Thoracic Surgeons (STS) Predicted Risk
of Mortality (STS-PROM),12 logistic EuroSCORE,12 and Charlson
comorbidity index.13 Frailty markers included a 5-m gait speed test14
and grip strength testing.15 Disability was assessed using Katz Activities
of Daily Living16 and a mini-mental status examination for dementia.
The intended treatment population included all patients accepted by the
Screening Committee and who were then enrolled or treated through an
alternative access in the study in the Alternative Access Arm.
Study Endpoints
The primary endpoint was the rate of all-cause mortality or major stroke
at 12 months after the procedure in the attempted implant population.
Major and minor stroke were defined using the Valve Academic Research
Consortium-1 criteria.17 The criteria for major adverse cardiovascular and
cerebral events included all-cause death, myocardial infarction, all stroke
events, and reintervention to alter, adjust, or replace a previously implanted
valve. Symptom status was assessed using the New York Heart Association
(NYHA) classification system. Serial echocardiograms were collected at
screening, after the procedure (within 24-48 hours), at hospital discharge,
and 1, 6, and 12 months after THV implantation and were interpreted by a
Central Laboratory (Mayo Echocardiography Core Laboratory, Rochester,
Minn). Prosthetic valve dysfunction and paravalvular regurgitation were
determined using Valve Academic Research Consortium-1 criteria.17
Statistical Analysis
The study had 1 primary objective—to assess the combined all-cause
mortality or major stroke rate at 12 months after treatment with the
self-expanding THV. Because the outcomes of patients unsuitable for
surgery who had prohibitive iliofemoral anatomy had not been previously
reported, no objective performance goal was included. The categorical
variables were compared using Fisher’s exact test or the chi-square test,
as appropriate. Continuous variables are presented as the mean standard
deviation and were compared using the Student t test. Kaplan-Meier
estimates were used to construct the survival curves using all available
follow-up data for the time-to-event analysis. All testing used a 2-sided
a level of 0.05. All statistical analyses were performed using Statistical
Analysis Systems software, version 9.2 (SAS Institute, Cary, NC).RESULTS
From February 2011 to August 2012, 150 patients with
prohibitive iliofemoral anatomy were enrolled at 41 centers
in the United States and treated with the CoreValve THV
(Figure 1). After enrollment completion of the CoreValve
Extreme Risk US Pivotal Trial, an additional 339 patients
were treated at 45 clinical sites in the Continued Access
Study and had 30 days of follow-up data available for
analysis.The Journal of Thoracic and CarPatient Demographics
The demographics and anatomic contraindications to
SAVR for patients in the Pivotal Study and Continued
Access Study are reported in Table 1. The patients in the
Pivotal Study were elderly (age, 81.3  7.4 years),
commonly women (54.7%), and severely symptomatic
(NYHA class III or IV, 92.0%). The mean Society for
Thoracic Surgeons Predicted Risk of Mortality was
10.7%  5.7% and exceeded 15% in 17.3% of the
patients. A history of atrial fibrillation was present in
48.3% of patients. No significant differences were found
in the standard demographics between the patients enrolled
in the Alternative Access Arms of the Pivotal Trial and the
Continued Access Study.
Using Society of Thoracic Surgeons criteria, severe lung
disease was present in 39.3% of the patients, and home
oxygen therapy was used in 44.0% of the patients
(Table 2). Of the patients, 68.0% had severe comorbidities
when categorized using the Charlson comorbidity index.
The average 5-m gait speed was>6 seconds for 81.7% of
patients, and the grip strength was less than the age- and
sex-matched threshold for 75.0% of the patients. Objectivediovascular Surgery c Volume 148, Number 6 2871
TABLE 1. Patient baseline demographics
Demographic data
Pivotal
(n ¼ 150)
Continued
access
(n ¼ 339)
P
value
Age (y) 81.3  7.4 81.8  8.2 .50
Female sex 82 (54.7) 170 (50.1) .38
NYHA classification .23
Class II 12 (8.0) 42 (12.4)
Class III 98 (65.3) 224 (66.1)
Class IV 40 (26.7) 73 (21.5)
STS-PROM (%) 10.7  5.7 10.1  5.6 .23
STS-PROM level .25
<10% 75 (50.0) 195 (57.5)
10%-15% 49 (32.7) 88 (26.0)
>15% 26 (17.3) 56 (16.5)
Logistic EuroSCORE (%) 22.9  15.9 24.2  17.2 .45
Diabetes mellitus 51 (34.0) 134 (39.5) .27
CKD class 4/5 21 (14.1) 48 (14.4) 1.00
History of hypertension 137 (91.3) 308 (90.9) 1.00
PVD 92 (61.3) 213 (68.1) .15
Previous stroke 21 (14.1) 48 (14.2) 1.00
Previous TIA 16 (10.7) 34 (10.1) .87
Cardiac risk factors
Coronary artery disease 120 (80.0) 277 (81.7) .71
Previous CABG 61 (40.7) 118 (34.8) .22
Previous PCI 48 (32.0) 138 (40.7) .07
Previous balloon valvuloplasty 34 (22.7) 68 (20.1) .55
Previous pacemaker/defibrillator 38 (25.3) 66 (19.5) .15
Previous myocardial infarction 49 (32.7) 104 (30.7) .67
Previous atrial fibrillation/atrial
flutter
72 (48.3) 154 (45.8) .62
Unfavorable anatomy
Aorta calcification .67
Severe 25 (16.8) 61 (18.0)
Porcelain 12 (8.1) 21 (6.2)
Chest wall deformity 3 (2.0) 7 (2.1) 1.00
Hostile mediastinum 13 (8.7) 23 (6.8) .46
Data presented as mean standard deviation or n (%). Denominator was 489, unless
otherwise indicated. NYHA, New York Heart Association; STS-PROM, Society of
Thoracic Surgeons Predicted Risk of Mortality; CKD, chronic kidney disease; PVD,
peripheral vascular disease; TIA, transient ischemic attack; CABG, coronary artery
bypass grafting; PCI, percutaneous coronary intervention; EuroSCORE, European
System for Cardiac Operative Risk Evaluation.
TABLE 2. Comorbidities and frailty
Assessment
Pivotal
(n ¼ 150)
Continued
access
(n ¼ 339)
P
value
Comorbidities
STS chronic lung disease <.05
None 42 (28.0) 125 (36.9)
Mild 27 (18.0) 59 (17.4)
Moderate 22 (14.7) 62 (18.3)
Severe 59 (39.3) 93 (27.4)
Home oxygen use 66 (44.0) 116 (34.2) .04
FEV1<1000 mL 51 (34.0) 93 (27.4) .12
DLCO<50% 60 (40.0) Not performed
Liver cirrhosis 1 (0.7) 6 (1.8) .68
Connective tissue disease 3 (2.0) 14 (4.1) .29
Immunosuppressive therapy 28 (18.7) 70 (20.6) .71
Charlson comorbidity index 5.7  2.2 5.6  2.3 .96
None (score 0) 0 (0.0) 0 (0.0) .27
Mild (score 1, 2) 9 (6.0) 13 (3.8)
Moderate (score 3, 4) 39 (26.0) 108 (32.0)
Severe (score 5) 102 (68.0) 217 (64.2)
Frailty
Anemia with transfusion 36 (24.7) 83 (25.5) .91
BMI<21 kg/m2 22 (14.7) 55 (16.2) .79
Albumin<3.3 g/dL 25 (17.1) 65 (19.5) .61
Unplanned weight loss 21 (14.0) 44 (13.0) .77
Fall within past 6 mo 30 (20.0) 63 (18.6) .71
5-m Gait speed>6 s 98 (81.7) 257 (89.2) .05
Grip strength less than threshold 111 (75.0) 247 (74.4) .91
Disabilities
Living in assisted living facility 24 (16.0) 38 (11.2) .14
ADLs
Deficit 1 ADLs 42 (28.0) 61 (18.0) .02
Deficit 2 ADLs 29 (19.3) 39 (11.5) .02
Deficit 3 ADLs 15 (10.0) 27 (8.0) .49
Dementia according to MMSE score
None (25) 110 (73.8) 250 (74.0) .49
Mild (21-24) 29 (19.5) 74 (21.9)
Moderate (10-20) 10 (6.7) 13 (3.8)
Severe (<10) 0 (0.0) 1 (0.3)
STS, Society of Thoracic Surgeons; FEV1, forced expiratory volume in 1 second;
DLCO, diffusion capacity of lung carbon monoxide; BMI, body mass index;
ADLs, activities of daily living; MMSE, mini-mental state examination.
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(Table 2). The rates of STS severe lung disease (P<.05),
home oxygen use (P ¼ .04), and disability using the
Katz Activities of Daily Living (P ¼ .02) were less for
the patients enrolled in the Continued Access Study than
for those enrolled in the Pivotal Trial.
Subclavian Approach
A total of 70 patients (46.7%) underwent THV
implantation using the subclavian approach. The mean total
procedure time was 67.3  52.6 minutes (median, 54.0).
The distribution of CoreValve valve sizes was 23 mm in
0.0%, 26 mm in 42.0%, 29 mm in 53.6%, and 31 mm in
4.3%. During the procedure, packed red blood cells were2872 The Journal of Thoracic and Cardiovascular Suradministered to 11.4% of the patients, and 1.4% received
a transfusion of packed red blood cells of 4 U. Postim-
plantation balloon valvuloplasty was performed in 13.0%
of the patients. No events of device migration or emboliza-
tion occurred. None of the patients required emergency
conversion to surgery because of coronary obstruction.
None of the patients underwent a concomitant percutaneous
coronary intervention. Two valves were implanted in 2.9%
of the patients.
Direct Aortic Approach
Of the 150 patients, 80 (53.3%) underwent THV
implantation using the direct aortic approach. The meangery c December 2014
TABLE 3. Clinical outcomes at 12 months in the Alternative Access
Pivotal Study*
Outcome Pivotal (n ¼ 150)
Death from any cause or major stroke 59 (39.4)
Death
From any cause 54 (36.0)
Cardiovascular 42 (28.8)
Stroke 18 (13.0)
Major 13 (9.1)
Minor 6 (4.7)
TIA 3 (2.3)
MACCE 62 (41.4)
Myocardial infarction 3 (2.1)
Periprocedural 2 (1.3)
Spontaneous 1 (0.7)
Reintervention 1 (1.0)
Major or life-threatening bleeding 96 (65.1)
Life-threatening or disabling 43 (29.4)
Major 60 (41.9)
Major vascular complications 14 (9.5)
Acute kidney injury 21 (14.2)
Permanent pacemaker placementy 30 (21.5)
Cardiogenic shock 9 (6.0)
Cardiac perforation 2 (1.3)
Device migration 0 (0.0)
Device embolization 0 (0.0)
Data presented as n (%). TIA, Transient ischemic attack; MACCE, major adverse
cardiovascular and cerebrovascular events. *All percentages are Kaplan-Meier
estimates at the specific point and thus do not equal the number of patients divided
by the total number in the study group. yPatients with pacemaker or implantable
cardioverter defibrillator at baseline included.
FIGURE 2. Changes in mean aortic valve gradient (blue) and mean
effective orifice area (red) during the study period at each follow-up point.
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40.5). The distribution of the CoreValve valve sizes was
23 mm in 11.4%, 26 mm in 40.5%, 29 mm in 45.6%,
and 31 mm in 2.5%. During the procedure, packed red
blood cells were administered to 35.0% of the patients,
and 3.8% received a transfusion of packed red blood cells
of 4 U. Postimplantation balloon valvuloplasty was per-
formed in 13.9% of the patients. No episodes of device
migration or embolization occurred, and no patient required
implantation of >1 prosthesis. None of the patients
developed coronary obstruction requiring emergency
surgical bypass surgery. None of the patients underwent a
concomitant percutaneous coronary intervention. None of
the patients had 2 valves implanted.
Clinical Outcomes
By 30 days, the primary endpoint of death or major
stroke had occurred in 23 patients (15.3%). Of the 23
patients, 17 (11.3%) had died and 11 (7.5%) had experi-
enced major stroke (some patients experienced both).
The clinical outcomes at 30 days in the Pivotal and
Continued Access Studies are listed in Tables E3 and E4.
The rates were slightly lower in the Continued Access
Study, with death or major stroke in 40 patients (11.9%;The Journal of Thoracic and Car32 [9.5%] died and 10 [3.0%] experienced major stroke;
Table E3).
In the attempted implant population, the primary
endpoint of the rate of all-cause mortality or major stroke
at 12 months was 39.4%, with an upper 95% confidence
interval of 47.2% (Figure E2; Table 3). The rate of
all-cause mortality at 12 months was 36.0% and the rate
of major stroke at 12 months was 9.1%. Permanent
pacemaker implantation was required in 24 patients
(16.4%) by 30 days and 30 patients (21.5%) by 1 year.
The NYHA class mean had improved significantly from
baseline to the 12-month follow-up point (D 1.4  0.8;
P < .0001). At baseline, most patients (91.9%) were
in NYHA class III or IV, and at each subsequent follow-
up visit, most patients were in NYHA class I or II
(Figure E3).
The echocardiographic data showed a baseline aortic
valve area of 0.72  0.27 cm2 and mean aortic valve
gradient of 49.5  17.0 mm Hg. After CoreValve TAVR,
the effective aortic valve area was 1.82  0.64 cm2 at 1
month and 1.85  0.51 cm2 at 12 months. The mean
aortic valve gradient was 9.7  5.8 mm Hg at 1 month
and 9.5  5.7 mm Hg at 12 months (Figure 2). The degree
of paravalvular regurgitation decreased during the follow-
up period, with no regurgitation present in 33.6% of
patients immediately after TAVR and 47.6% at 1 year.
Moderate to severe paravalvular leak was present in 7.0%
at discharge and 2.4% at 1 year (Figure E4). Paired analysis
showed that 85.7% of patients with moderate or severe
paravalvular leak at discharge had improved by 12 months.DISCUSSION
We studied alternative access approaches to TAVR using
the CoreValve prosthesis to treat severe aortic stenosis in a
cohort of patients who had not been studied previously.
The patients had been deemed by a local interdisciplinary
heart team and a national screening committee to be at
extreme risk if undergoing conventional surgery. These
decisions were determined using traditional surgical riskdiovascular Surgery c Volume 148, Number 6 2873
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tic EuroSCORE,19 and also included subjective assess-
ments that incorporated factors beyond those included
in the STS-PROM and EuroSCORE predictive models.
Unlike previous populations, the patients in present study
(23.5%; 150 of the 639 ‘‘attempted patients’’ in the Pivotal
Trial) also had peripheral vascular disease severe enough to
prohibit placement of an 18F femoral sheath. We found
that alternative access TAVR with the CoreValve prosthesis
in this ‘‘no option’’ population was associated with an
acceptable rate of death or major stroke at 12 months
(39.4%). Implantation of this self-expanding aortic
bioprothesis also provided sustained improvement in the
aortic valve effective orifice area, a reduction in the
mean aortic valve gradient with low rates of aortic insuffi-
ciency, and an overall improvement in the NYHA func-
tional class.
Mortality and Major Stroke
Within the present trial, no prespecified performance
goal was identified, because no suitable standard was
available to allow estimation of event rates in either
treated or untreated patients. However, peripheral vascular
disease has been shown in multiple studies to be an
independent predictor of mortality in multiple studies of
general populations, patients treated medically, and those
undergoing surgery, with risk ratios as high as 4.1.20 Thus,
mortality in the Extreme Risk Pivotal Trial Alternative
Access Arm might be expected to exceed the rates among
patients undergoing femoral access TAVR. Within the
PARTNER B trial, nonfemoral access was not allowed
in patients who had been deemed inoperable. Transapical
TAVR was permitted only in patients in the PARTNER A
trial who were operable but with high surgical risk. Within
the latter trial, the mortality rate 1 year after transapical
TAVR was greater than that reported after transfemoral
TAVR (29.0% vs 22.2%).2 The 30-day mortality rate of
11.3% in our study was greater than the 5.0% reported
in PARTNER Cohort B1 or the 8.4% reported in the
CoreValve Extreme Risk Trial Iliofemoral Arm4 (both of
which required femoral access) but was comparable to
the 30-day mortality rate of 10.6% in the PARTNER A
high-risk transapical group21 and the 30-day mortality
rate of 12.6% in inoperable patients who were treated
with the alternative access and the SAPIEN valve
(Lifesciences) in the Transcatheter Valve Therapy
Registry.22 As expected, the rate of major stroke at 1
year of 9.1% was similar to the 7.8% rate reported in
PARTNER Cohort B and comparable to the 10.8%
reported in the PARTNER Cohort A transapical group.21
Taken in aggregate, these findings suggest strongly that
the relatively high event rates were in large part likely
to be a consequence of the advanced degree of illness in
this patient group.2874 The Journal of Thoracic and Cardiovascular SurAortic Regurgitation
The results of our study have demonstrated a relatively
low rate of moderate or severe paravalvular aortic
valve regurgitation (2.4%) 1 year after CoreValve THV
placement. This rate was lower than those previously
reported and most likely attributable to precise valve sizing
according to the computed tomography assessment of the
aortic annular diameter,23,24 more precise placement of
the bioprosthesis within the aortic annulus using access
routes shorter than those for the femoral approach, and
the use of postdilatation when significant paravalvular
regurgitation was noted during the procedure. The
prevalence of moderate aortic regurgitation in our patients
decreased during the follow-up period, suggesting ongoing
remodeling of the annular–bioprothesis interface with the
self-expanding device.Conduction System Disturbances
Conduction system disturbances can occur after
CoreValve TAVR owing to the mechanical trauma
applied by the inflow portion of the valve frame to the mem-
branous septum in the region of the atrioventricular conduc-
tion system and left bundle branch.25,26 Accordingly,
the need for a permanent pacemaker placement after
CoreValve THV implantation has been reported to range
from 25.8% to 33.0%.27,28 Although placement of a
permanent pacemaker does not seem to affect late
mortality,29 we used ‘‘best practices’’ to reduce the occur-
rence of conduction disturbances during TAVR, including
smaller predilatation balloons, valve sizing using computed
tomography guidance, and higher positioning of the
CoreValve THV, with avoidance of the conduction sys-
tem.30 In the present study, the rate of permanent pacemaker
implantation was 16.4% at 30 days.Subclavian Versus Direct Aortic Access
Subclavian access resulted in lower 30-day all-cause
mortality rate than the direct aortic access (8.6% vs
13.7%) but a greater major stroke rate (8.6% vs 6.5%,
respectively). The conduct of the trial in patients not
suitable for femoral access was to move to subclavian
access next and then direct aortic access, if subclavian
access, was not considered feasible. Direct aortic access
requires a more invasive approach than subclavian, and
because it is the last approach to consider, these patients
might also represent a different risk group.Continued Access
We included data from patients enrolled in the Continued
Access Study, who had been enrolled between the point of
enrollment completion in the Pivotal Study and Food and
Drug Administration approval of the CoreValve THV and
who had 30 days of follow-up data to analyze. Thegery c December 2014
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observed in the Pivotal Trial, but the patients treated in
the Continued Access Study had lower rates of disabilities
(Table 2). Coupled with a procedural learning curve, this
might have contributed to the lower rates of 30-day mortal-
ity (9.5%) and major stroke (3.0%). In the nonrandomized
continued access portion of the PARTNER A trial, similar
observations included improvement in the transapical
TAVR outcomes as site experience increased.21A
C
DStudy Limitations
Although the present study is the first to describe the
outcomes of a new technique in a hitherto unexplored
population, it had several limitations. First, because of
ethical concerns surrounding the futility of medical
treatment for patients with symptomatic severe aortic
stenosis, the study was performed without a medically
managed control group. The novelty of the present
population also made it impossible to determine a virtual
event rate for a control group, which would have been
required to establish a performance standard, such as was
done in the CoreValve Extreme Risk US Pivotal Trial
Iliofemoral Arm. Thus, although we consider it a reason-
able assumption that treatment of these patients using
noniliofemoral access is superior to medical therapy alone,
the statement cannot be made with absolute certainty.
However, some reassurance can be found in the observation
by the PARTNER Cohort A investigators that in a lower risk
group of patients, the 1-year outcomes after transapical
TAVR were not different than those after surgical AVR. A
second limitation was that the number of patients enrolled
in the present study was inadequate to permit a reliable
comparison between the subclavian and direct aortic
approaches to TAVR.CONCLUSIONS
The results of the present study have demonstrated
that noniliofemoral alternative access for TAVR with the
CoreValve prosthesis is technically feasible and associated
with acceptable rates of death or major stroke, low rates
of moderate or severe aortic insufficiency, and marked
improvements in symptomatic status in patients with
severe aortic stenosis who are at prohibitive risk of
surgical AVR.References
1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al.
Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot
undergo surgery. N Engl J Med. 2010;363:1597-607.
2. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al.
Transcatheter versus surgical aortic-valve replacement in high-risk patients.
N Engl J Med. 2011;364:2187-98.
3. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb MG, et al.
Transcatheter aortic-valve replacement with a self-expanding prosthesis.
N Engl J Med. 2014;370:1790-8.The Journal of Thoracic and Car4. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D,
et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis
in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Car-
diol. 2014;63:1972-81.
5. Petronio AS, De Carlo M, Bedogni F, Maisano F, Ettori F, Klugmann S, et al.
2-Year results of CoreValve implantation through the subclavian access: a
propensity-matched comparison with the femoral access. J Am Coll Cardiol.
2012;60:502-7.
6. Schafer U, Ho Y, Frerker C, Schewel D, Sanchez-Quintana D, Schofer J, et al.
Direct percutaneous access technique for transaxillary transcatheter aortic valve
implantation: ‘‘the Hamburg Sankt Georg approach.’’ JACC Cardiovasc Interv.
2012;5:477-86.
7. Testa L, Brambilla N, Laudisa ML, De Carlo M, Lanotte S, Latini RA, et al.
Right subclavian approach as a feasible alternative for transcatheter aortic valve im-
plantationwith theCoreValveReValvingSystem.EuroIntervention. 2012;8:685-90.
8. Bruschi G, De Marco F, Botta L, Oreglia J, Colombo P, Paino R, et al.
Direct transaortic CoreValve implantation through right minithoracotomy in
patients with patent coronary grafts. Ann Thorac Surg. 2012;93:1297-9.
9. Bruschi G, de Marco F, Botta L, Cannata A, Oreglia J, Colombo P, et al.
Direct aortic access for transcatheter self-expanding aortic bioprosthetic valves
implantation. Ann Thorac Surg. 2012;94:497-503.
10. Bruschi G, De Marco F, Botta L, Oreglia J, Colombo P, Colombo T, et al.
Trans-aortic access for transcatheter aortic valve implantation: single center
experience. JACC. 2011;58:B208.
11. Ramlawi B, Bedeir K, Barker C, Lin CH, Kleiman N, Reardon M. Direct aortic
and subclavian access for transcatheter aortic valve replacement: decision
making and technique. J Thorac Cardiovasc Surg. 2014;148:353-6.
12. O’Brien S, Shahian D, Filardo G, Ferraris V, Haan C, Rich J, et al. The Society of
Thoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve
surgery. Ann Thorac Surg. 2009;88:S23-42.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40:373-83.
14. Afilalo J, Eisenberg MJ, Morin JF, Bergman H, Monette J, Noiseux N, et al. Gait
speed as an incremental predictor of mortality and major morbidity in elderly
patients undergoing cardiac surgery. J Am Coll Cardiol. 2010;56:1668-76.
15. Bohannon RW, Bear-Lehman J, Desrosiers J, Massy-Westropp N, Mathiowetz V.
Average grip strength: a meta-analysis of data obtained with a Jamar
dynamometer from individuals 75 years or more of age. J Geriatr Phys Ther.
2007;30:28-30.
16. Katz S, Ford AB,Moskowitz RW, Jackson BA, JaffeMW. Studies of illness in the
aged. The index of ADL: a standardized measure of biological and psychosocial
function. JAMA. 1963;185:914-9.
17. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, et al.
Standardized endpoint definitions for transcatheter aortic valve implantation
clinical trials: a consensus report from the Valve Academic Research
Consortium. J Am Coll Cardiol. 2011;57:253-69.
18. Green P, Woglom AE, Genereux P, Daneault B, Paradis JM, Schnell S, et al.
The impact of frailty status on survival after transcatheter aortic valve
replacement in older adults with severe aortic stenosis: a single-center
experience. JACC Cardiovasc Interv. 2012;5:974-81.
19. Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE.
Eur Heart J. 2003;24:881-2.
20. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and
mortality implications. Circulation. 2006;114:688-99.
21. Dewey TM, Bowers B, Thourani VH, Babaliaros V, Smith CR, Leon MB, et al.
Transapical aortic valve replacement for severe aortic stenosis: results from the
nonrandomized continued access cohort of the PARTNER trial. Ann Thorac
Surg. 2013;96:2083-9.
22. Mack MJ, Brennan JM, Brindis R, Carroll J, Edwards F, Grover F, et al.
Outcomes following transcatheter aortic valve replacement in the United States.
JAMA. 2013;310:2069-77.
23. Binder RK, Webb JG, Willson AB, Urena M, Hansson NC, Norgaard BL, et al.
The impact of integration of a multidetector computed tomography annulus
area sizing algorithm on outcomes of transcatheter aortic valve replacement:
a prospective, multicenter, controlled trial. J Am Coll Cardiol. 2013;62:431-8.
24. Jilaihawi H, Kashif M, Fontana G, Furugen A, Shiota T, Friede G, et al.
Cross-sectional computed tomographic assessment improves accuracy of aortic
annular sizing for transcatheter aortic valve replacement and reduces the
incidence of paravalvular aortic regurgitation. J Am Coll Cardiol. 2012;59:
1275-86.diovascular Surgery c Volume 148, Number 6 2875
Acquired Cardiovascular Disease Reardon et al
A
C
D25. Piazza N, Onuma Y, Jesserun E, Kint PP, Maugenest AM, Anderson RH, et al.
Early and persistent intraventricular conduction abnormalities and requirements
for pacemaking after percutaneous replacement of the aortic valve. JACC
Cardiovasc Interv. 2008;1:310-6.
26. Fraccaro C, Buja G, Tarantini G, Gasparetto V, Leoni L, Razzolini R, et al.
Incidence, predictors, and outcome of conduction disorders after transcatheter
self-expandable aortic valve implantation. Am J Cardiol. 2011;107:747-54.
27. ErkapicD, DeRosa S, KelavaA, LehmannR, Fichtlscherer S, Hohnloser SH.Risk
for permanent pacemaker after transcatheter aortic valve implantation: a compre-
hensive analysis of the literature. J Cardiovasc Electrophysiol. 2012;23:391-7.
28. Khawaja MZ, Rajani R, Cook A, Khavandi A, Moynagh A, Chowdhary S, et al.
Permanent pacemaker insertion after CoreValve transcatheter aortic valve im-
plantation: incidence and contributing factors (the UK CoreValve Collaborative).
Circulation. 2011;123:951-60.
29. Buellesfeld L, Stortecky S, Heg D, Hausen S, Mueller R, Wenaweser P, et al.
Impact of permanent pacemaker implantation on clinical outcome among
patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol.
2012;60:493-501.
30. Piazza N, Nuis RJ, Tzikas A, Otten A, Onuma Y, Garcia-Garcia H, et al. Persis-
tent conduction abnormalities and requirements for pacemaking six months after
transcatheter aortic valve implantation. EuroIntervention. 2010;6:475-84.Discussion
Dr FriedrichM.Mohr (Leipzig, Germany). Dr Reardon, thank
you very much for this excellent presentation and also for
providing the report in advance, which only had the 150 patients
in writing compared with 338 patients right now in your talk,
which is, of course, something I could not review in advance.
I will focus on the 150 patients in your report. In this analysis,
you report the early and 1-year outcome of 150 patients with
severe aortic stenosis and aortoiliac and femoral stenosis. All
patients were treated using the transcatheter CoreValve system
for aortic valve replacement through an alternative route, which
was, in 70 times, the subclavian artery, or in 80 times, the direct
aortic approach.
All patients could be treated successfully. In some of the
patients, 2 valves were implanted. Perhaps you can expand on
that, whether it was 1 patient who received 2, a valve-in-valve,
or 2 patients. A number of 2.9 did not make any sense to me.
This is question 1.
By 30 days, the primary endpoint of death and major stroke had
occurred in 23 or 15% of the patients. You further reported that
death occurred in 17 patients or 11.3%, and major stroke in 11
or 17.5%. If you sum the data, 11 and 17, this does not equal 23.
This somehow does not fit together. So, I have a mathematical
problem.
The reported stroke rates seem to be greater compared with
those from other studies, such as the SAPIENAortic Bioprosthesis
European Outcome (SOURCE) Registry identified major access
complications associated with high 30-day mortality and/or the
German Aortic Valve Registry reporting on transapical access
implanting other alternative valves compared with the CoreValve.
Can you comment on that?2876 The Journal of Thoracic and Cardiovascular SurFinally, I congratulate you on the reported results in this
high-risk population. Although, a control group is lacking, the
published data from the past 10 years has proved the benefit
of TAVR versus medical treatment. It would be interesting to
randomly compare all alternative routes, including the transapical
approach.
Dr Reardon. Thank you, Dr Mohr.
As far as the question about the SOURCE registry and GARY,
of course, these are registries with self-reported data. In the
CoreValve trial, we already knew that the Food and Drug Admin-
istration was keenly interested in stroke; thus, every patient in the
CoreValve Pivotal Trial had a National Institutes of Health stroke
scale assessment before treatment and a National Institutes of
Health stroke scale assessment immediately after treatment. If
any changes at all were found, the patient underwent a neurologic
evaluation and imaging studies.
Thus, we actually studied the data a lot more than registries
have tended to or that the PARTNER trial did because the study
of the data was all retrospective. So, it was not surprising if we
had a greater incidence of strokes, because if you look harder,
you tend to find more.
Additionally, transapical access was not allowed in the
nonoperable extreme risk patients in the PARTNER B trial,
and most of the patients in the registries you mentioned were
high- to intermediate-risk patients. These were not high-risk
patients as you stated but extreme risk patients comparable to those
in the PARTNER B trial.
I believe the 339 additional patients in the continued access
group were included in the report, and I apologize for any
confusion. The number of patients who required the use of 2 valves
was 2.9% and included those with a valve-in-valve and those who
had had the first valve removed and a second valve placed, ending
with only 1 valve in place but 2 valves used.
The question about death or major stroke at 30 days occurring in
23 patients, death as an isolated event in 17 and major stroke as an
isolated event in 11 does add up, because some patients
experienced both major stroke and death. They were therefore
counted individually in each the death and major stroke isolated
categories but only once in the death or major stroke group,
because this is an ‘‘or’’ statement.
Dr Mohr. Okay.
Dr Reardon. However, there are some differences, and, again,
I think, 1 of the differences, when you try to compare our study to
registries such as SOURCE or GARYor the France II or UK, is that
this was really a single-arm longitudinal study that demands data
input. It requires outside monitoring. It requires outside clinical
events review. It demands outside core laboratories, and it fits all
the criteria of a very strict Food and Drug Administration trial.
So it does make it a unique way of looking at this.
Dr Mohr. Thank you.gery c December 2014
FIGURE E1. CoreValve transcatheter heart valve. The self-expanding
nitinol frame serves to anchor the transcatheter heart valve at the level of
the aortic annulus. The supra-annular trileaflet porcine pericardial valve
is hand sewn to the nitinol frame.
FIGURE E2. Cumulative event curve for all-cause mortality or major
stroke. Event rates were calculated using the Kaplan-Meier method.
Brackets indicate 95% confidence intervals.
FIGURE E3. New York Heart Association (NYHA) classification during
the study period. Symptom status according to NewYorkHeart Association
class is shown at baseline and 30 days, 6 months, and 12months for patients
undergoing attempted transcatheter aortic valve replacement.
FIGURE E4. Changes in paravalvular regurgitation during the study
period. The percentage of patients by degree of paravalvular aortic
regurgitation is shown at each follow-up interval. TAVR, Transcatheter
aortic valve replacement.
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TABLE E1. Participating investigational sites and personnel
Center Location
Banner Good Samaritan Phoenix, Ariz
Baylor Heart and Vascular Hospital Dallas, Tex
Beth Israel Deaconess Medical Center Boston, Mass
Cardiovascular Institute of the South Houma, La
Detroit Medical Center Cardiovascular Institute Detroit, Mich
Duke University Medical Center Durham, NC
El Camino Hospital Mountain View, Calif
Fletcher Allen Health Care Burlington, Vt
Geisinger Medical Center Danville, Pa
Hartford Hospital Hartford, Conn
Inova Fairfax Hospital, Inova Heart and Vascular
Institute
Falls Church, Va
Iowa Heart Center Des Moines, Iowa
Kaiser Permanente Los Angeles Medical Center Los Angeles, Calif
Lenox Hill Hospital New York, NY
Loyola University Medical Center Maywood, Ill
Morristown Memorial Hospital Morristown, NJ
Mount Sinai Medical Center Miami Beach, Fla
New York University/Langone Medical Center New York, NY
North Shore University Hospital Manhasset, NY
Piedmont Heart Institute Atlanta, Ga
Pinnacle Health Harrisburg, Pa
Providence Sacred Heart Medical Center Spokane, Wash
Riverside Methodist Hospital/Ohio Health
Research Institute
Columbus, Ohio
Saint Joseph’s Hospital of Atlanta Atlanta, Ga
Spectrum Health Hospitals Grand Rapids, Mich
St Francis Hospital Roslyn, NY
St John Hospital and Medical Center Detroit, Mich
St Luke’s Medical Center, Aurora Health Center Milwaukee, Wis
St Vincent Heart Center of Indiana Indianapolis, Ind
Texas Heart Institute, St Luke’s Episcopal
Hospital/Baylor College of Medicine
Houston, Tex
Houston-Methodist-Debakey Heart and Vascular
Center/Methodist Hospital
Houston, Tex
Johns Hopkins University Hospital Baltimore, Md
Mount Sinai Medical Center New York, NY
Ohio State University Medical Center,
The Richard M. Ross Heart Hospital
Columbus, Ohio
University Hospitals/Case Medical Center Cleveland, Ohio
University of Kansas Hospital Kansas City, Kan
University of Miami Health System Miami, Fla
University of Michigan Health System Ann Arbor, Mich
University of Pittsburgh Medical Center Pittsburgh, Pa
University of Southern California, University
Hospital
Los Angeles, Calif
Veterans Affairs Palo Alto Health Care System Palo Alto, Calif
Vanderbilt University Medical Center Nashville, Tenn
Wake Forest University Baptist Medical Center Winston-Salem, NC
Washington Hospital Center, Georgetown
Hospital
Washington, DC
Yale New Haven Hospital, Yale University
School of Medicine
New Haven, Conn
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TABLE E2. CoreValve US Pivotal Study organization
Steering committee Jeffrey Popma (co-chair), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass;
Thomas Armitage (co-chair), Structural Heart, Medtronic, Inc, Mounds View, Minn
Cardiac surgeons: David Adams, Mount Sinai Medical Center, New York, NY; John Byrne, Vanderbilt
University School of Medicine, Nashville, Tenn; Joseph Coselli, Texas Heart Institute, Houston, Tex;
Tom Gleason, University of Pittsburgh Medical Center, Pittsburgh, Pa; G. Michael Deeb, University of
Michigan, Ann Arbor, Mich; Michael Reardon, Houston-Methodist-Debakey Heart and Vascular
Center, Houston, Tex
Interventional cardiologists: William Anderson, University of Pittsburgh Medical Center, Pittsburgh, Pa;
James Hermiller, St Vincent Heart Center of Indiana, Indianapolis, Ind; Steven Yakubov, Riverside
Methodist Hospital/Ohio Health Research Institute, Columbus, Ohio; Maurice Buchbinder, Veterans
Affairs Palo Alto Health Care System, San Diego, Calif
Consultants: Patrick Serruys, Thoraxcenter, Erasmus University, Rotterdam, The Netherlands; Blase
Carabello, Baylor College of Medicine, Houston, Tex
Screening committee Cardiac surgeons: David H. Adams, Mount Sinai Medical Center, New York, NY; John Byrne, Vanderbilt
University, Nashville, Tenn; Thomas G. Gleason, University of Pittsburgh Medical Center, Pittsburgh,
Pa; G.Michael Deeb, University ofMichigan, Ann Arbor, Mich;Michael Reardon, Houston-Methodist-
Debakey Heart and Vascular Center, Houston, Tex (chair); John Conte, Johns Hopkins Medical Center,
Baltimore, Md
Interventional cardiologists: Steven Yakubov, Riverside Methodist Hospital/Ohio Health Research
Institute, Columbus, Ohio; Jeffrey J. Popma, Beth Israel Deaconess Medical Center, Boston, Mass
Site monitoring Global Clinical Operations, Medtronic, Inc, Mounds View, Minn
Electronic database Oracle Clinical, Oracle Corporation, Redwood Shores, Calif
Data management Global Clinical Operations, Medtronic, Inc, Mounds View, Minn
Biostatistics Structural Heart, Medtronic, Inc, Mounds View, Minn; Harvard Clinical Research Institute, Boston, Mass
Data safety monitoring board David Faxon (chair, IC), Brigham and Women’s Hospital, Boston, Mass; William Holman (CS),
Birmingham, Ala; John Orav (biostatistics), Brigham and Women’s Hospital, Boston, Mass; Scott E.
Kasner (neurologist), Hospital of the University of Pennsylvania; John J. Lopex (IC), Loyola University,
Maywood, Ill
Safety officer Tom Vassiliades, Jr, Office of Medical Affairs, Structural Heart, Medtronic, Inc, Mounds View, Minn
Clinical events committee Cardiac or vascular surgeons (CS): Ed Gravereaux, Brigham and Women’s Hospital, Boston, Mass;
Roberto Rodriguez, Caritas St Elizabeth Medical Center, Brighton, Mass; Sanjay Samy, Guthrie Clinic,
Sayre, Pa
Interventional cardiologists (IC): Cliff Berger, Boston Medical Center, Boston, Mass; Donald Cutlip, Beth
Israel Deaconess Medical Center, Boston, Mass; Carey Kimmelstiel, New England Medical Center,
Boston, Mass; Sergio Waxman, Lahey Medical Center, Burlington, Mass
Neurologists: John Dashe, New England Medical Center, Boston, Mass; David Thaler, Lahey Medical
Center, Burlington, Mass
Heart failure specialist: David DeNofrio, New England Medical Center, Boston, Mass
Echocardiography core laboratory Jae K. Oh, Mayo Echocardiography Core Laboratory, Rochester, Minn
ECG core laboratory Peter Zimetbaum, Harvard Clinical Research Institute, Boston, Mass
Economic and quality of life core laboratory David Cohen, Mid-America Medical Center, Kansas City, Mo; Matthew Reynolds, Harvard Clinical
Research Institute, Boston, Mass
Global proctors Raoul Bonan, Montreal, Quebec, Canada; Stephen Brecker, St George’s Hospital, London, UK; Haim
Danenberg, Hadassah Hebrew University, Jerusalem, Israel; Eberhard Grube, Heart Center Siegburg,
Germany; Anders Jonsson, Karolinska, Stockholm, Sweden; Iassen Michev, New York, NY;
Jean-Claude Laborde, Clinique Pasteur, Toulouse, France
ECG, Electrocardiography; IC, interventional cardiologist; CS, cardiac or vascular surgeon.
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TABLE E3. Clinical outcomes at 30 days*
Outcome
Pivotal
(n ¼ 150)
Continued
access
(n ¼ 339)
P
value
Death from any cause or major stroke 23 (15.3) 40 (11.9) .28
Death
From any cause 17 (11.3) 32 (9.5) .55
Cardiovascular 17 (11.3) 32 (9.5) .55
Stroke 13 (8.8) 18 (5.4) .16
Major 11 (7.5) 10 (3.0) .03
Minor 3 (2.1) 8 (2.4) .79
TIA 2 (1.4) 1 (0.3) .18
MACCE 26 (17.3) 52 (15.4) .60
Myocardial infarction 3 (2.1) 4 (1.2) .48
Periprocedural 2 (1.3) 4 (1.2) .89
Spontaneous 1 (0.7) 0 (0.0) .13
Reintervention 0 (0.0) 2 (0.6) .35
Major or life-threatening bleeding 87 (58.3) 184 (54.4) .51
Life-threatening or disabling 36 (24.2) 80 (23.7) .95
Major 55 (37.1) 110 (32.7) .37
Major vascular complications 13 (8.7) 14 (4.2) .04
Permanent pacemaker placementy 24 (16.4) 60 (18.2) .64
Acute kidney injury 21 (14.2) 48 (14.5) .89
Cardiogenic shock 9 (6.0) 21 (6.2) .93
Cardiac perforation 2 (1.3) 7 (2.1) .58
TIA, Transient ischemic attack; MACCE, major adverse cardiovascular and
cerebrovascular events. *All percentages presented as Kaplan-Meier estimates at
the specific point and thus do not equal the number of patients divided by the total
number in the study group. yPatients with pacemaker or implantable cardioverter
defibrillator at baseline were included.
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TABLE E4. Clinical outcomes at 30 days*
Outcome
Subclavian Direct aortic
Pivotal (n ¼ 70)
Continued access
(n ¼ 76) P value Pivotal (n ¼ 80)
Continued access
(n ¼ 260) P value
Death from any cause or major stroke 10 (14.3) 5 (6.8) .13 13 (16.2) 34 (13.1) .5
Death
From any cause 6 (8.6) 3 (4.2) .25 11 (13.7) 28 (10.8) .5
Cardiovascular 6 (8.6) 3 (4.2) .25 11 (13.7) 28 (10.8) .5
Stroke 6 (8.6) 6 (7.9) .85 7 (9.1) 12 (4.7) .17
Major 6 (8.6) 3 (3.9) .24 5 (6.5) 7 (2.7) .14
Minor 1 (1.5) 3 (3.9) .36 2 (2.5) 5 (2.0) .76
TIA 1 (1.5) 0 (0.0) .29 1 (1.3) 1 (0.4) .38
MACCE 10 (14.3) 9 (12.1) .67 16 (20.0) 42 (16.2) .45
Myocardial infarction 1 (1.4) 1 (1.3) .95 2 (2.6) 3 (1.2) .38
Periprocedural 1 (1.4) 1 (1.3) .95 1 (1.2) 3 (1.2) .94
Spontaneous 0 (0.0) 0 (0.0) NA 1 (1.4) 0 (0.0) .07
Reintervention 0 (0.0) 1 (1.3) .34 0 (0.0) 1 (0.4) .58
Major or life-threatening bleeding 31 (44.6) 23 (30.3) .09 56 (70.3) 161 (62.1) .20
Life-threatening or disabling 7 (10.2) 8 (10.5) .91 29 (36.4) 72 (27.8) .15
Major 27 (39.2) 15 (19.8) .01 28 (35.3) 95 (36.9) .82
Major vascular complications 10 (14.3) 6 (7.9) .22 3 (3.8) 8 (3.1) .78
Acute kidney injury 6 (8.7) 3 (3.9) .25 15 (19.0) 45 (17.7) .83
Permanent pacemaker placementy 8 (11.8) 18 (23.7) .06 16 (20.6) 42 (16.7) .42
Cardiogenic shock 3 (4.3) 2 (2.6) .58 6 (7.5) 19 (7.3) .95
Cardiac perforation 1 (1.4) 2 (2.6) .61 1 (1.2) 5 (1.9) .69
Device migration 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) NA
Device embolization 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) NA
Data presented as n (%). Three patients in the attempted implant cohort of Continued Access Study Alternative Access Arm had procedures aborted before attempting access
through a subclavian or direct aortic route and their data were not included. TIA, Transient ischemic attack; MACCE, major adverse cardiovascular and cerebrovascular events;
NA, not applicable. *All percentages presented as Kaplan-Meier estimates at the specific point and thus do not equal the number of patients divided by the total number in the study
group. yPatients with a pacemaker or implantable cardioverter defibrillator at baseline were included.
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TABLE E5. Major clinical event definitions
Death*
All-cause death
All deaths from any cause after valve intervention (including all cardiovascular and noncardiovascular deaths)
Cardiovascular death
Any death from proximate cardiac cause (eg, MI, cardiac tamponade, worsening heart failure)
Unwitnessed death and death of unknown cause
All procedure-related deaths, including those related to a complication of the procedure or treatment of a complication of the procedure
Death caused by noncoronary vascular conditions (eg, cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting
aneurysm, or other vascular disease)
All deaths within 30 d of procedure
Noncardiovascular death
Any death not covered by the above definitions (eg, death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide,
or trauma)
Valve-related death
Any death caused by prosthetic valve dysfunction, valve thrombosis, embolism, bleeding event, or implanted valve endocarditis
Death related to reintervention on the operated valve
Stroke*
Neurologic events were defined as
Rapid onset of a focal or global neurologic deficit with 1 of the following: change in level of consciousness, hemiplegia, hemiparesis,
numbness or sensory loss affecting 1 side of the body, dysphasia or aphasia, hemianopia, Amaurosis fugax, or other neurologic signs or
symptoms consistent with stroke
Duration of a focal or global neurologic deficit  24 h; OR<24 h, if therapeutic interventions were performed (eg, thrombolytic therapy or
intracranial angioplasty); OR available neuroimaging studies documenting a new hemorrhage or infarct; OR the neurologic deficit resulted
in death
No other readily identifiable nonstroke cause for the clinical presentations (eg, brain tumor, trauma, infection, hypoglycemia, peripheral lesion,
pharmacologic influence)*
Confirmation of the diagnosis by 1 of the following:
Neurology or neurosurgical specialist
Neuroimaging procedure (MRI or CT or cerebral angiography)
Lumbar puncture (spinal fluid analysis diagnostic of intracranial hemorrhage)
Stroke definitions
Transient ischemia attack
A new focal neurologic deficit with rapid symptom resolution (usually 1-2 h) and always within 24 h
Neuroimaging without tissue injury
Stroke (diagnosed as above, preferably with positive neuroimaging findings)
Minor: modified Rankin<2 at 30 and 90 d
Major: modified Rankin  2 at 30 and 90 dy
Myocardial infarction*
Periprocedural MI (72 h after the index procedure)
New ischemic symptoms (eg, chest pain or shortness of breath) or new ischemic signs (eg, ventricular arrhythmias, new or worsening heart
failure, new ST-segment changes [elevation>1 mm or depression>1 mm in  2 contiguous leads], hemodynamic instability; or imaging
evidence of new loss of viable myocardium or new wall motion abnormality) AND
Elevated cardiac biomarker evidence (preferably creatinine kinase-MB) within 72 h after the index procedure, consisting of  2 postprocedure
samples 6-8 h apart with a 20% increase in the second sample and a peak value>10 times the 99th percentile URL or a peak value
>5 times the 99th percentile URL and with new pathologic Q waves in  2 contiguous leads
Spontaneous MI (>72 h after the index procedure), including any of the following
Detection of increase and/or decrease in cardiac biomarkers (preferably troponin) with 1 value greater than the 99th percentile URL, together
with evidence of myocardial ischemia with  1 of the following
ECG changes indicative of new ischemia (new ST-T changes or new LBBB)
New pathologic Q waves in  2 contiguous leads
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by
presumably new ST elevation, or new LBBB, and/or evidence of fresh thrombus by coronary angiography and/or at autopsy, but death
occurring before blood samples could be obtained or before the appearance of cardiac biomarkers in the blood
Pathologic findings of acute MI
(Continued)
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TABLE E5. Continued
Bleeding events*
Life-threatening or disabling bleeding
Fatal bleeding OR
Bleeding in a critical area or organ (eg, intracranial, intraspinal, intraocular, or pericardial, necessitating pericardiocentesis,
or intramuscular with compartment syndrome) OR
Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery OR
Overt source of bleeding with decrease in hemoglobin of  5 g/dL or whole blood or packed RBC transfusion of  4 U
Major bleeding
Overt bleeding associated with a decrease in hemoglobin level of  3.0 g/dL or requiring transfusion of 2 or 3 U of whole blood RBCs
AND not meeting criteria for life-threatening or disabling bleeding
Major vascular complications*
Any thoracic aortic dissection
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, arteriovenous fistula, pseudoaneurysm, hematoma,
irreversible nerve injury, or compartment syndrome) leading to death, need for significant blood transfusions ( 4 U), unplanned
percutaneous or surgical intervention, or irreversible end-organ damage (eg, hypogastric artery occlusion causing visceral ischemia
or spinal artery injury causing neurologic impairment)
Distal embolization (noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage
Device success*
Successful vascular access, delivery, and deployment of the device and successful retrieval of the delivery system
Correct position of the device in the proper anatomic location (placement in the annulus with no impedance on device function)
Intended performance of the prosthetic heart valve (aortic valve area  1.2 cm2 for 26-, 29-, and 31-mm valves or  0.9 cm2 for 23-mm
valves) and mean aortic valve gradient<20 mm Hg or peak velocity<3 m/s without moderate or severe prosthetic valve aortic
regurgitation
Only 1 valve implanted in the proper anatomic location
MI, Myocardial infarction; MRI, magnetic resonance imaging; CT, computed tomography; URL, upper reference limit; ECG, electrocardiographic; LBBB, left bundle branch
block; RBC, red blood cell. *Adapted from Leon and colleagues.17 yDiscrepancies between the modified Rankin score at 90 d were adjudicated by the Clinical Events Committee.
Reardon et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 148, Number 6 2876.e7
A
C
D
